摘要
目的评价莫西沙星短程治疗社区获得性肺炎(CAP)的疗效及安全性。方法87例轻中度CAP患者随机分为两组。对照组(传统疗程组)予莫西沙星静脉治疗10 d;短程治疗组予莫西沙星静脉治疗5 d。结果①对照组和短程治疗组痊愈率分别为68.2%(30/44)和65.1%(28/43),临床有效率分别为90.9%(40/44)和88.4%(38/43),细菌清除率分别为88.2%(30/34)和87.9%(29/33);这三个指标中,两组间比较差异均无统计学意义。②对照组和短程治疗组不良反应发生率分别为9.1%(4/44)和7.0%(3/43),两组间比较差异无统计学意义。结论莫西沙星短程治疗社区获得性肺炎效果与莫西沙星传统疗程治疗相似,较安全。
Objective To evaluate the efficacy, safety of short - course moxifloxacin therapy in the treatment of community - acquired pneumonia. Methods This analysis was based on the outcomes in 87 patients with mild to moderate community - acquired pneumonia. Patients were randomized to receive moxifloxaein therapy for l0 days （control group ） or 5 days （short - course therapy group）. Results ①The overall cure rates and efficacy rates were 68.2% and 90.9% in control group, 65.1% and 88.4% in short - course therapy group, respectively. The bacterial clearance rates were 88.2% in control group and 87.9% in shortcourse therapy group, respectively. There was no significant difference between the two groups in the above resuhs （P 〉 0.05） . ②The incidences of adverse drug reaction were 9. 1% in control group and 7.0% in short- course therapy group, respectively. There was no significant difference between the two groups（ P 〉 0.05 ） . Conclusion The short -course moxifloxacin therapy in the treatment of community - acquired pneumonia was as effective and safe as the standard therapy.
出处
《临床医学》
CAS
2008年第11期4-6,共3页
Clinical Medicine
基金
江苏大学2005年临床医学科技发展基金资助项目(JLY20050041)
关键词
莫西沙星
短程治疗
社区获得性肺炎
Moxifloxacin
Short - course therapy
Community - acquired pneumonia
